Total Funding
5
Total FundingSeries A raised
Growth Score in past quarter
pts
Heat Score 5 in past quarter
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3701640
Padlock is developing medicines targeting PADs, immune complexes in autoimmune diseases, and more.
Acquired by 
Bristol-Myers Squibb
About the Company
Padlock is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation,
and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs.
Padlock was founded by scientists at The
Scripps Research Institute and members of the Atlas Venture Life Sciences Team. Padlock's investors include Atlas Venture, Johnson & Johnson, and MS Ventures.
Padlock is a seed company operating out of the Atlas Venture office in Cambridge MA.

